icd-10 code for jak2 testing

CPT codes 81270 (JAK2), 81338 (MPL), 81339 (MPL), 81279 (JAK2 exons 12 and 13), 81219 (CALR), and 0027U (JAK2 exons 12-15) are considered medically necessary for the following ICD-10-CM codes when criteria in Indications and Limitations of Coverage are met: Group 14 Codes

Full Answer

What is the sensitivity of the JAK2 test?

Other mutations that may occur in the JAK2 gene will not be detected. In vitro studies have indicated that this assay has an analytical sensitivity of 1%. This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).

What mutations will not be detected by the JAK2 test?

Mutations occurring outside of the analyzed region of the JAK2 gene will not be detected by this assay. This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration. Reverse transcription polymerase chain reaction RT-PCR and Sanger sequencing

What is the prevalence of JAK2V617F mutation?

The JAK2V617F mutation is found in almost all patients with polycythemia vera (PV) and in nearly one-half of those with idiopathic myelofibrosis (IMF) and with essential thrombocythemia (ET). A small percentage (~3.3%) of JAK2 mutation positive patient contain other non- V617F mutations within exons 12 to 15.

How do I contact customer service for JAK2 testing?

Please provide indications for JAK2 testing and specimen type. Direct any questions regarding this test to customer service at 800-345-4363. Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider.

What is a JAK2 test?

The JAK2 mutation test is typically ordered as a follow-up test if a person has a significantly increased hemoglobin, hematocrit, red blood cells and/or platelet count and the healthcare practitioner suspects that the person may have an MPN, especially polycythemia vera (PV), essential thrombocythemia (ET), or primary ...

Does Medicare cover JAK2?

For laboratories performing next generation sequencing (NGS or "hotspot") testing platforms: Molecular testing for BCR-ABL, JAK 2, JAK, exon 12, and CALR/MPL genes by NGS is covered as medically necessary for the identification of myeloproliferative disorders.

What is another name for JAK2?

Janus kinase 2; JAK2.

What is JAK2 disorder?

Somatic mutations in the JAK2 gene are associated with essential thrombocythemia, a disorder characterized by an increased number of platelets, the blood cells involved in normal blood clotting.

Is CPT code 81206 genetic testing?

CPT® 81206, Under Genetic Analysis Procedures The Current Procedural Terminology (CPT®) code 81206 as maintained by American Medical Association, is a medical procedural code under the range - Genetic Analysis Procedures.

What is procedure code 81406?

CPT CODE: 81406. BRAF SEQUENCING – KNOWN VARIANT. CPT CODE: 81403.

What is the ICD 10 code for myeloproliferative disorder?

1.

Is JAK2 a leukemia mutation?

JAK2 mutations are rare in de novo acute myeloid leukemia (AML), and JAK2-mutated acute myeloid leukemia (AML) patients usually have a previous history of myeloproliferative neoplasms (MPNs).

How do you test for JAK2 mutation?

Your doctor can use a blood sample or a bone marrow sample from a biopsy to check your JAK2 gene. You can get results in four to six days, but your lab may take longer. SOURCES: Mayo Clinic: “Polycythemia Vera,” “Complete blood count (CBC),” “Bone marrow biopsy and aspiration.”

What chromosome is JAK2 on?

Chromosome 9Janus kinase 2Gene location (Human)Chr.Chromosome 9 (human)Band9p24.1StartEnd2 more rows

What is MPN medical term?

Myeloproliferative neoplasms, or MPNs — also called myeloproliferative disorders, or MPDs — are a collection of blood disorders that are believed to be caused by mutations in bone marrow stem cells.

Is polycythemia a blood disorder?

Polycythemia vera is a rare blood disorder in which there is an increase in all blood cells, particularly red blood cells. The increase in blood cells makes your blood thicker. This can lead to strokes or tissue and organ damage.

What mutation is detected in PCR?

The quantitative real-time PCR assay detects V617F mutation (c.1849 G>T) observed in approximately 95% polycythemia vera (pv), 55% essential thrombocythemia (ET), and 55% primary myelofibrosis (PMF). It is also infrequently present (3% to 5%) in myelodysplastic syndrome, chronic myelomonocytic leukemia, and other atypical chronic myeloid disorders. The results should be interpreted in the context of all clinical and laboratory findings. No therapeutic action should be taken based solely on these results.

Does the JAK2V617F test detect other mutations?

This assay detects only the JAK2V617F point mutation. Other mutations that may occur in the JAK2 gene will not be detected. In vitro studies have indicated that this assay has an analytical sensitivity of 1%. This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).

What is the cascading reflex of JAK2?

JAK2 V617F Cascading Reflex to CALR, JAK2 Exon 12, MPL, and CSF3R - This DNA-based cascading reflex identifies the disease-defining mutations in four genes used for diagnosis and follow-up of myeloproliferative neoplasms (MPNs) including polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) and chronic neutrophilic leukemia (CNL).#N#Since these mutations are essentially mutually exclusive, reporting is done in a stepwise fashion based on mutation frequencies assessing JAK2 V617F, then exon 9 of CALR (calreticulin), then exon 12 of JAK2, then codon 505 and 515 of MPL, and then two mutational hotspots in the CSF3R gene. Once a pathogenic ...

Is the Quest Diagnostics test cleared?

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

General Information

CPT codes, descriptions and other data only are copyright 2020 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Article Guidance

Article Text Article Text This article contains coding and other guidelines that complement the Local Coverage Determination (LCD) for Molecular Pathology Procedures. Specific Coding of Molecular Testing Panels The submission of claims using individual gene CPT codes, when either 5-50 or >50 gene panels are ordered, is considered incorrect coding.

Bill Type Codes

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the article does not apply to that Bill Type.

Revenue Codes

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the article, services reported under other Revenue Codes are equally subject to this coverage determination.

Expected Turnaround Time

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Container

Lavender-top (EDTA) tube, green-top (sodium heparin) tube or yellow-top (ACD) tube

Causes for Rejection

Specimen does not meet all of the criteria for sample type, container, minimum volume, collection and storage; frozen whole blood or marrow; leaking tube; clotted blood or marrow; grossly hemolyzed or otherwise visibly degraded; contamination by another specimen; specimen containing foreign material

Limitations

In vitro studies indicate that this analysis has a mutation detection sensitivity of 15%. Mutations occurring outside of the analyzed region of the JAK2 gene will not be detected by this assay.

Methodology

Reverse transcription polymerase chain reaction RT-PCR and Sanger sequencing

General Information

CPT codes, descriptions and other data only are copyright 2020 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Article Guidance

This Billing and Coding Article provides billing and coding guidance for molecular pathology services, genomic sequencing procedures and other multianalyte assays, multianalyte assays with algorithmic analyses, and applicable proprietary laboratory analyses codes and Tier 1 and Tier 2 molecular pathology procedures.

ICD-10-CM Codes that Support Medical Necessity

It is the provider’s responsibility to select codes carried out to the highest level of specificity and selected from the ICD-10-CM code book appropriate to the year in which the service is rendered for the claim (s) submitted.

Bill Type Codes

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the article does not apply to that Bill Type.

Revenue Codes

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the article, services reported under other Revenue Codes are equally subject to this coverage determination.